Literature DB >> 21960648

Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study.

Daniel Mueller1, Mark Obermann, Min-Suk Yoon, Franziska Poitz, Niels Hansen, Marc-Andre Slomke, Peter Dommes, Elke Gizewski, Hans-Christoph Diener, Zaza Katsarava.   

Abstract

OBJECTIVE: To estimate the lifetime prevalence of trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) in a population-based sample in Germany.
METHODS: A total of 3336 responders of 6000 contacted inhabitants of the city of Essen in Germany were screened using a self-assessment questionnaire. 327 individuals, who reported recurrent facial pain and randomly selected 150 (5% of 3009) screening negative subjects, received a phone interview by one of six neurologists and if necessary a face-to-face examination. Those with suspected TN or PIFP following the phone interview underwent neurological examination by two neurologists who were unaware of the presumed diagnosis. A random group of 25 (10% of 247) phone interview negative subjects was examined face-to-face. All suspected cases of PIFP received otorhinolaryngological examination and diagnostic cranial magnetic resonance imaging (MRI). In TN patients the number of vessel-nerve contacts was determined by thin-slice cranial MRI.
RESULTS: Lifetime prevalence of TN was estimated to be 0.3% [10 of 3336; 95% CI 0.1-0.5%], of PIFP 0.03% [1 of 3336; 95% CI < 0.08%]. Thin-slice cranial MRI detected five vessel-nerve contacts and no symptomatic lesions in the 10 TN patients.
CONCLUSIONS: This large population-based study revealed that TN and PIFP are rare facial pain disorders.

Entities:  

Mesh:

Year:  2011        PMID: 21960648     DOI: 10.1177/0333102411424619

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  45 in total

Review 1.  Interventions for Refractory Trigeminal Neuralgia: A Bayesian Mixed Treatment Comparison Network Meta-Analysis of Randomized Controlled Clinical Trials.

Authors:  Kannan Sridharan; Gowri Sivaramakrishnan
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

Review 2.  Botulinum Toxin Treatment in Multiple Sclerosis-a Review.

Authors:  Yasaman Safarpour; Tahereh Mousavi; Bahman Jabbari
Journal:  Curr Treat Options Neurol       Date:  2017-08-17       Impact factor: 3.598

3.  Trigeminal neuralgia increases cerebral blood flow in a focal cerebral ischemic model in rats.

Authors:  Wei Wang; Weiliang Zhao; Zhenxiu Liu; Jianhua Xia; Jingru Wu; Xueyin Shi
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 4.  Facial Pain Update: Advances in Neurostimulation for the Treatment of Facial Pain.

Authors:  Rajivan Maniam; Alan David Kaye; Nalini Vadivelu; Richard D Urman
Journal:  Curr Pain Headache Rep       Date:  2016-04

Review 5.  Trigeminal neuralgia.

Authors:  Joanna M Zakrzewska; Mark E Linskey
Journal:  BMJ Clin Evid       Date:  2014-10-06

Review 6.  Atypical Facial Pain: a Comprehensive, Evidence-Based Review.

Authors:  Austin L Weiss; Ken P Ehrhardt; Reda Tolba
Journal:  Curr Pain Headache Rep       Date:  2017-02

Review 7.  Interventional procedures for facial pain.

Authors:  Kevin E Vorenkamp
Journal:  Curr Pain Headache Rep       Date:  2013-01

8.  First application of 7-T ultra-high field diffusion tensor imaging to detect altered microstructure of thalamic-somatosensory anatomy in trigeminal neuralgia.

Authors:  John W Rutland; Kuang-Han Huang; Corey M Gill; Dillan F Villavisanis; Judy Alper; Gaurav Verma; Joshua B Bederson; Bradley N Delman; Raj K Shrivastava; Priti Balchandani
Journal:  J Neurosurg       Date:  2019-08-30       Impact factor: 5.115

9.  Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Authors:  Ahmad Fallata; Amber Salter; Tuula Tyry; Gary R Cutter; Ruth Ann Marrie
Journal:  Int J MS Care       Date:  2017 Sep-Oct

Review 10.  [Headache. Current status of research and treatment].

Authors:  A Straube; C Gaul
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.